[Skip to Content]
[Skip to Content Landing]
May 1987

Comments on Continued Clinical Research on Systemic Aminocaproic Acid for Traumatic Hyphema

Author Affiliations

Gainesville, Fla

Arch Ophthalmol. 1987;105(5):611-612. doi:10.1001/archopht.1987.01060050029010

To the Editor.  —I was aghast to view the publication of yet another clinical research study1 of the effectiveness of aminocaproic acid administered systemically to prevent rebleeding episodes in traumatic hyphema.This is the third such excellent study to prove without challenge the same point: it does work. But in both of the earlier studies,2,3 there was a significant number of patients in the control group who suffered rebleeding episodes who might well have been spared that discomfort and complication and even surgery(!) had the authors accepted the first study and simply treated their patients as recommended by the authors of the first study. In this latest study, 23% of patients who received the placebo treatment rebled, while none who received aminocaproic acid rebled. Admittedly, that represents only three people—but two required surgery and one, multiple procedures. How can one justify this?In the introduction to this last